ImmunologybioRxiv
Inhibition of CDK4/6 Overcomes Primary Resistance to PD-1 Blockade in Malignant Mesothelioma
H.-J. Jang, C. Y. Truong, E. M. Lo…·H.-S. Lee
This study identifies CDK4/6 as a therapeutic target to overcome primary resistance to PD-1 blockade in malignant mesothelioma by analyzing genomic and immunogenomic data.
DOI 10.1016/j.athoracsur.2021.08.054